211 related articles for article (PubMed ID: 32059430)
1. Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity.
Berenguer D; Alcover MM; Sessa M; Halbaut L; Guillén C; Boix-Montañés A; Fisa R; Calpena-Campmany AC; Riera C; Sosa L
Pharmaceutics; 2020 Feb; 12(2):. PubMed ID: 32059430
[TBL] [Abstract][Full Text] [Related]
2. Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis.
Berenguer D; Sosa L; Alcover M; Sessa M; Halbaut L; Guillén C; Fisa R; Calpena-Campmany AC; Riera C
Pharmaceutics; 2019 Nov; 11(11):. PubMed ID: 31731660
[TBL] [Abstract][Full Text] [Related]
3. Development, characterization, and anti-leishmanial activity of topical amphotericin B nanoemulsions.
Dos Santos Matos AP; Lopes DCDXP; Peixoto MLH; da Silva Cardoso V; Vermelho AB; Santos-Oliveira R; Viçosa AL; Holandino C; Ricci-Júnior E
Drug Deliv Transl Res; 2020 Dec; 10(6):1552-1570. PubMed ID: 32676952
[TBL] [Abstract][Full Text] [Related]
4. Co-delivery of amphotericin B and pentamidine loaded niosomal gel for the treatment of
Anjum A; Shabbir K; Din FU; Shafique S; Zaidi SS; Almari AH; Alqahtani T; Maryiam A; Moneeb Khan M; Al Fatease A; Bashir S; Khan GM
Drug Deliv; 2023 Dec; 30(1):2173335. PubMed ID: 36722301
[TBL] [Abstract][Full Text] [Related]
5. Preparation and Characterization of Nanostructured Lipid Carriers for Improved Topical Drug Delivery: Evaluation in Cutaneous Leishmaniasis and Vaginal Candidiasis Animal Models.
Riaz A; Hendricks S; Elbrink K; Guy C; Maes L; Ahmed N; Kiekens F; Khan GM
AAPS PharmSciTech; 2020 Jul; 21(5):185. PubMed ID: 32632542
[TBL] [Abstract][Full Text] [Related]
6. New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp.
Ruiz HK; Serrano DR; Dea-Ayuela MA; Bilbao-Ramos PE; Bolás-Fernández F; Torrado JJ; Molero G
Int J Pharm; 2014 Oct; 473(1-2):148-57. PubMed ID: 24998510
[TBL] [Abstract][Full Text] [Related]
7. Amphotericin B-loaded deformable lipid vesicles for topical treatment of cutaneous leishmaniasis skin lesions.
Carvalheiro M; Vieira J; Faria-Silva C; Marto J; Simões S
Drug Deliv Transl Res; 2021 Apr; 11(2):717-728. PubMed ID: 33534106
[TBL] [Abstract][Full Text] [Related]
8. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
[TBL] [Abstract][Full Text] [Related]
9. Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.
Jaafari MR; Hatamipour M; Alavizadeh SH; Abbasi A; Saberi Z; Rafati S; Taslimi Y; Mohammadi AM; Khamesipour A
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():156-165. PubMed ID: 31582344
[TBL] [Abstract][Full Text] [Related]
10. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
[TBL] [Abstract][Full Text] [Related]
11. Topical amphotericin B in ultradeformable liposomes: Formulation, skin penetration study, antifungal and antileishmanial activity in vitro.
Perez AP; Altube MJ; Schilrreff P; Apezteguia G; Celes FS; Zacchino S; de Oliveira CI; Romero EL; Morilla MJ
Colloids Surf B Biointerfaces; 2016 Mar; 139():190-8. PubMed ID: 26709977
[TBL] [Abstract][Full Text] [Related]
12. Efficacious treatment of experimental leishmaniasis with amphotericin B-arabinogalactan water-soluble derivatives.
Golenser J; Frankenburg S; Ehrenfreund T; Domb AJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2209-14. PubMed ID: 10471566
[TBL] [Abstract][Full Text] [Related]
13. Novel and safe single-dose treatment of cutaneous leishmaniasis with implantable amphotericin B-loaded microparticles.
Sousa-Batista AJ; Pacienza-Lima W; Ré MI; Rossi-Bergmann B
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():148-155. PubMed ID: 31331828
[TBL] [Abstract][Full Text] [Related]
14. Bovine serum albumin nanoparticles containing amphotericin B were effective in treating murine cutaneous leishmaniasis and reduced the drug toxicity.
Casa DM; Scariot DB; Khalil NM; Nakamura CV; Mainardes RM
Exp Parasitol; 2018 Sep; 192():12-18. PubMed ID: 30026113
[TBL] [Abstract][Full Text] [Related]
15.
Chanmol W; Siriyasatien P; Intakhan N
PeerJ; 2022; 10():e12813. PubMed ID: 35111411
[No Abstract] [Full Text] [Related]
16. Amphotericin B-Loaded Extracellular Vesicles Derived from
Davari A; Hajjaran H; Khamesipour A; Mohebali M; Mehryab F; Shahsavari S; Shekari F
Iran J Parasitol; 2023; 18(4):514-525. PubMed ID: 38169565
[TBL] [Abstract][Full Text] [Related]
17. In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion.
Rochelle do Vale Morais A; Silva AL; Cojean S; Balaraman K; Bories C; Pomel S; Barratt G; do Egito EST; Loiseau PM
Exp Parasitol; 2018 Sep; 192():85-92. PubMed ID: 30075233
[TBL] [Abstract][Full Text] [Related]
18. Development of a Topical Amphotericin B and
Espinoza LC; Sosa L; Granda PC; Bozal N; Díaz-Garrido N; Chulca-Torres B; Calpena AC
Pharmaceuticals (Basel); 2021 Oct; 14(10):. PubMed ID: 34681257
[TBL] [Abstract][Full Text] [Related]
19. Lipid formulations of amphotericin b in the treatment of experimental visceral leishmaniasis due to Leishmania infantum.
Gangneux JP; Sulahian A; Garin YJ; Derouin F
Trans R Soc Trop Med Hyg; 1996; 90(5):574-7. PubMed ID: 8944278
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.
Corral MJ; Serrano DR; Moreno I; Torrado JJ; Domínguez M; Alunda JM
J Antimicrob Chemother; 2014 Dec; 69(12):3268-74. PubMed ID: 25096077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
